Evidence map›Paper›PMID 35935911›Full record

ArticleArab journal of urology2022

The R.E.N.A.L score's relevance in determining perioperative and oncological outcomes: a Middle-Eastern tertiary care center experience.

Nassib Abou Heidar, Nizar Hakam, Jose M El-Asmar, Jad Najdi, Mark A Khauli, Jad Degheili, Albert El-Hajj, Rami Nasr, Wassim Wazzan, Muhammad Bulbul and 2 more

Abstract read
In one paragraph

Article in Arab journal of urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nassib Abou HeidarDivision of Urology and Renal Transplantation, American University of Beirut Medical Center, Beirut, Lebanon.ORCID https://orcid.org/0000-0003-3811-5543
Nizar HakamThe Breyer Lab, University of California San Francisco, San Francisco, California, United States.
Jose M El-AsmarDivision of Urology and Renal Transplantation, American University of Beirut Medical Center, Beirut, Lebanon.
Jad NajdiDivision of Urology and Renal Transplantation, American University of Beirut Medical Center, Beirut, Lebanon.
Mark A KhauliMassachussets General Hospital, Boston Massachussets.
Jad DegheiliDivision of Urology and Renal Transplantation, American University of Beirut Medical Center, Beirut, Lebanon.
Albert El-HajjDivision of Urology and Renal Transplantation, American University of Beirut Medical Center, Beirut, Lebanon.
Rami NasrDivision of Urology and Renal Transplantation, American University of Beirut Medical Center, Beirut, Lebanon.
Wassim WazzanDivision of Urology and Renal Transplantation, American University of Beirut Medical Center, Beirut, Lebanon.
Muhammad BulbulDivision of Urology and Renal Transplantation, American University of Beirut Medical Center, Beirut, Lebanon.
Deborah MukherjiDivision of Urology and Renal Transplantation, American University of Beirut Medical Center, Beirut, Lebanon.
Raja KhauliDivision of Urology and Renal Transplantation, American University of Beirut Medical Center, Beirut, Lebanon.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The aim of this study is to evaluate the significance of the R.E.N.A.L nephrometry scoring system in predicting perioperative and oncological outcomes and determining the surgical approach of choice for kidney tumors.Patients and Methods: Our study retrospectively reviewed outcomes from the year 2002 to 2017. Mann-Whitney U test was used to compare continuous variables and chi-square test was used to compare categorical variables. Kaplan-Meier estimates and multivariable cox proportional hazard regression were performed to determine an association between the different R.E.N.A.L categories and disease recurrence or mortality. Results: A total of 325 patients underwent kidney surgery The most common R.E.N.A.L score category in our cohort study was intermediate (41.2%), followed by low, (33.2%) and high (25.5%). Patients with a high R.E.N.A.L score had worse perioperative outcomes compared to those with a low R.E.N.A.L score. High R.E.N.A.L score patients were 3 times more likely to receive blood transfusions compared to those with a low R.E.N.A.L score (19.4% vs 6.3%, p = 0.018), and a statistically significant longer hospital length of stay was also observed between the two groups (median 4.5 vs 4 days, p = 0.0419). In addition, the only predictor of disease recurrence or mortality was a high R.E.N.A.L score (Hazard Ratio (HR) 3.65, 95% Confidence Interval (CI) 1.05-12.7, p = 0.041). Conclusion: Our study sheds light on the use of R.E.N.A.L nephrometry score in predicting perioperative, postoperative, and oncological outcomes. Such findings may play a role in optimizing surgical approaches and pre-operative patient counseling.

Indexed as

Kidney cancerkidney tumoroutcomesrenal cell cancerRENAL score

Identifiers

PMID35935911
PMCPMC9354629

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.